{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:15:01Z","timestamp":1791321301699,"version":"4.3.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.antiviral.2011.07.018","type":"journal-article","created":{"date-parts":[[2011,8,8]],"date-time":"2011-08-08T19:32:18Z","timestamp":1312831938000},"page":"364-368","source":"Crossref","is-referenced-by-count":76,"title":["The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants"],"prefix":"10.1016","volume":"92","author":[{"given":"Sunwen","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Marousek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Auerochs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stamminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Milbradt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2011.07.018_b0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(03)15162-8","article-title":"Artesunate combinations for treatment of malaria: meta-analysis","volume":"363","author":"Adjuik","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2011.07.018_b0005","doi-asserted-by":"crossref","first-page":"e10370","DOI":"10.1371\/journal.pone.0010370","article-title":"Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers","volume":"5","author":"Arav-Boger","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2011.07.018_b0010","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jviromet.2011.03.005","article-title":"A reporter system for Epstein-Barr virus (EBV) lytic replication: anti-EBV activity of the broad anti-herpesviral drug artesunate","volume":"173","author":"Auerochs","year":"2011","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.antiviral.2011.07.018_b0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1399-3062.2010.00550.x","article-title":"Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients","volume":"12","author":"Avery","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.07.018_b0020","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.07.018_b0025","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.49.7.2710-2715.2005","article-title":"Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene","volume":"49","author":"Chou","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.07.018_b0030","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/AAC.00207-06","article-title":"Effect of cell culture conditions on the anticytomegalovirus activity of maribavir","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.07.018_b0035","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1128\/AAC.00736-07","article-title":"Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens","volume":"51","author":"Chou","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.07.018_b0040","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1128\/JVI.01787-07","article-title":"Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant","volume":"82","author":"Chou","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.07.018_b0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/AAC.01177-08","article-title":"Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir","volume":"53","author":"Chou","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.07.018_b0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcv.2011.01.004","article-title":"Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy","volume":"50","author":"Chou","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2011.07.018_b0055","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00109-001-0300-8","article-title":"Antiviral activity of artesunate towards wild-type, recombinant and ganciclovir-resistant human cytomegaloviruses","volume":"80","author":"Efferth","year":"2002","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.antiviral.2011.07.018_b0060","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.freeradbiomed.2004.06.023","article-title":"Enhancement of cytotoxicity of artemisinins towards cancer cells by ferrous iron","volume":"37","author":"Efferth","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.antiviral.2011.07.018_b0065","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/591195","article-title":"The antiviral activities of artemisinin and artesunate","volume":"47","author":"Efferth","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.07.018_b0135","first-page":"8","article-title":"Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies","volume":"28","author":"Gomes","year":"2008","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.07.018_b0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.antiviral.2005.10.003","article-title":"The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo","volume":"69","author":"Kaptein","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2011.07.018_b0075","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2011.07.018_b0080","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.44.6.1588-1597.2000","article-title":"Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents","volume":"44","author":"Marschall","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.07.018_b0095","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2217\/fmb.09.40","article-title":"Molecular targets for antiviral therapy of cytomegalovirus infections","volume":"4","author":"Marschall","year":"2009","journal-title":"Future Microbiol."},{"key":"10.1016\/j.antiviral.2011.07.018_b0100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.07.018_b0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcv.2009.05.017","article-title":"Sensitivity of human herpesvirus 6 towards the broad-spectrum antiinfective drug artesunate","volume":"46","author":"Milbradt","year":"2009","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2011.07.018_b0110","series-title":"Fields Virology","first-page":"2701","article-title":"Cytomegaloviruses","author":"Mocarski","year":"2007"},{"key":"10.1016\/j.antiviral.2011.07.018_b0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.antiviral.2006.06.004","article-title":"Antiviral activity of arthrospira-derived spirulan-like substances","volume":"7","author":"Rechter","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2011.07.018_b0140","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1086\/587106","article-title":"Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation","volume":"46","author":"Shapira","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.07.018_b0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1086\/653122","article-title":"Virologic characterization of multi-drug-resistant cytomegalovirus infection in two transplant recipients treated with maribavir","volume":"202","author":"Strasfeld","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.07.018_b0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.antiviral.2011.03.184","article-title":"Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation","volume":"90","author":"Wolf","year":"2011","journal-title":"Antiviral Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211003895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211003895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T21:20:05Z","timestamp":1543612805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354211003895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0166354211003895"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2011.07.018","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}